Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Intellia Therapeutics, Inc. (NTLA)

Intellia Secures Up to $400 Million Senior Secured Debt Facility With OrbiMed

Mixed Impact 4 of 5 financing Written later

On September 4, 2026, Intellia Therapeutics entered a five-year senior secured credit agreement with OrbiMed that provides up to $400 million, with $75 million drawn at closing. The remaining $325 million is available in tranches tied to FDA approval of lonvo-z, revenue targets and an equity fundraising target, plus an uncommitted $100 million that requires mutual agreement. The debt adds to Intellia's obligations, carries a floating-rate interest cost and is secured by substantially all of the company's assets, including its intellectual property.

Key points

  • $75 million funded at closing on September 4, 2026; up to $325 million more available subject to milestones
  • Loans bear interest at the greater of 3.00% or one-month SOFR plus 6.15%, and mature September 4, 2031
  • Obligations secured on a first-priority basis by substantially all assets, including intellectual property
  • Covenants require at least $50 million of liquidity in controlled accounts until FDA approves the lonvo-z BLA

The filing

CompanyIntellia Therapeutics, Inc. (NTLA)
Form8-K, current report
Filed with the SECSep 4, 2026, 4:06 PM ET
Accession number0001193125-26-383645

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.